Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 10, 2026
PureCycle Technologies (PCT) Down -20% Year-to-Date but Shows Momentum

PureCycle Technologies (PCT) Down -20% Year-to-Date but Shows Momentum

Key Takeaways

  • PureCycle Technologies shares closed at $7.21 on August 7, 2026, reflecting a modest decline of approximately 1.2% over the trailing 30-day period, while the stock has lost roughly 20% year-to-date.
  • The company reported Q2 2026 revenue of $4.51 million — a 173% year-over-year increase and its sixth consecutive quarter of sequential revenue growth — but missed consensus estimates and posted a net loss of $142.2 million.
  • Operational momentum is building: the Ironton facility completed a planned turnaround ahead of schedule and under budget, achieved a record daily throughput, and commissioned in-house compounding capabilities.
  • A $450.5 million capital raise through equity and convertible notes significantly strengthened liquidity to $236.9 million, extending debt maturities and reducing near-term financial pressure.
  • Regulatory tailwinds — particularly New Jersey's recycled-content mandate and California's SB54 — are accelerating customer qualification cycles, while the Procter & Gamble partnership continues expanding across multiple product lines.
  • Analyst consensus rates PCT a "Moderate Buy" with an average price target of $11.75, though some independent valuation models suggest the stock may be overvalued relative to current fundamentals.

Where PCT Stands in the Market Right Now

PureCycle Technologies (PCT) enters the second half of 2026 in a transitional phase, balancing early-stage commercial traction against the reality of steep operating losses. The stock has traded in a wide range over the past year, with a 52-week low of $4.93 and a high of $15.49, reflecting the high-beta, sentiment-driven nature of a pre-profitability growth story. After a sharp selloff from mid-June through late July, PCT found support near the $5.85 level and rebounded roughly 23% into early August, aided by Q2 earnings commentary that emphasized operational achievements and a fortified balance sheet. With a market capitalization of approximately $1.3 billion and a beta of 2.57, the stock remains highly sensitive to both company-specific execution milestones and broader market shifts in the waste-recycling and sustainability sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Understanding PureCycle's Business and Edge

PureCycle Technologies operates a patented solvent-based purification recycling process originally developed by Procter & Gamble, designed to transform waste polypropylene into ultra-pure recycled resin branded as PureFive. The company's flagship Ironton, Ohio facility serves as the commercial proof-of-concept, with capacity to produce over 100 million pounds of recycled polypropylene annually at full utilization. PureCycle occupies a unique position in the circular plastics economy: its dissolution technology can process contaminated polypropylene waste that traditional mechanical recycling cannot handle, producing resin that meets stringent food-contact and cosmetic-packaging standards. This differentiates the company from conventional recyclers and positions it to capture premium pricing as brands face mounting regulatory pressure to incorporate recycled content. Key competitive advantages include exclusive licensing rights to P&G's technology, established relationships with major converters and brand owners, and a growing intellectual property portfolio. The company is also advancing international expansion with a planned $250 million facility in Thailand and a European project in Antwerp, Belgium.

Key Recent Developments for PCT

Several material developments have shaped investor sentiment around PureCycle in recent weeks. The Q2 2026 earnings report, released on August 6, was a central catalyst: while the company missed analyst estimates on both the top and bottom lines — reporting an adjusted loss of $0.80 per share against a consensus estimate of a $0.29 loss — the market response was tempered by forward-looking operational commentary. Management disclosed that the Ironton facility completed more than 170 reliability and quality improvement projects during its planned turnaround, established a new daily throughput record in June, and demonstrated production rates of 12,000 pounds per hour during testing. The commissioning of in-house compounding operations, now running 24 hours a day five days per week, allows PureCycle to tailor recycled-content blends directly for customers while reducing reliance on third-party compounders.

On the commercial front, the Procter & Gamble relationship reached an inflection point with Downy detergent caps entering commercial production, Tide caps slated for Q3 2026, and Vicks ZzzQuil lids targeted for Q4. Separately, Cleveland Kitchen deli containers containing 25% PureFive resin reached shelves at a major retailer in June. Regulatory momentum also intensified: New Jersey granted conditional recycled-content approval for PureFive in May, unlocking demand from quick-service restaurant converters facing a January 2027 compliance deadline. The company reported 17 active trials tied specifically to New Jersey mandates and shipped compounded product to all three major QSR cold-cup converters early in the third quarter.

Financially, the June capital raise of $450.5 million in gross proceeds — split between common stock and 4.75% convertible senior notes due 2032 — transformed the balance sheet. The company used a portion of the proceeds to repurchase $216 million of higher-coupon 7.25% convertible notes, pushing the nearest major put date from 2027 to 2030 and lowering ongoing interest costs. Total liquidity stood at $236.9 million at quarter-end, supplemented by an undrawn $200 million revolving credit facility.

What to Watch in the Second Half of 2026

The second half of 2026 represents a critical execution window for PureCycle. Management has maintained its target of achieving site-level monthly cash breakeven at Ironton during the second half, contingent on reaching approximately 40% to 50% utilization and sustained branded sales. Investors should monitor quarterly production volumes, the pace of customer qualifications — particularly the 37 programs that advanced at least one qualification stage — and whether QSR cold-cup trials convert into recurring commercial orders. New Jersey's food-contact exemption expiration in January 2027 and the step-up to 20% recycled-content requirements create a near-term demand catalyst that may become more visible in order book trends over the coming quarters.

On the international front, Thailand project financing remains a key binary event. The company is negotiating binding terms and targeting financial close by year-end, with groundbreaking expected in the second half of 2026 and operations commencing in 2028. Any delays in financing or permitting would likely extend the timeline before international revenue contributions materialize. In Europe, the Antwerp project continues through permitting, supported by a €40 million EU Innovation Fund grant. Investors should also track progress toward ISO certifications and any additional regulatory approvals that broaden PureFive's addressable market. Full-year project spending guidance of $45 million to $50 million represents elevated capital outflows that will need to be weighed against commercial revenue growth. While the strengthened balance sheet provides a multi-year runway, the path to profitability remains dependent on consistent operational execution and accelerating commercial adoption across food-contact, cosmetics, and industrial packaging end markets.

Using AI Tools for Deeper Trading Insights

In my own research process, I often turn to Tickeron’s AI Trading Bots to explore automated strategies and performance data across volatile names. The platform provides transparent metrics on various bots, allowing me to evaluate different approaches alongside traditional fundamental work and see how they align with stocks exhibiting sentiment-driven moves like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PCT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for PCT turns positive, indicating new upward trend

PCT saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PCT's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PCT just turned positive on July 27, 2026. Looking at past instances where PCT's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PCT advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for PCT moved below the 200-day moving average on July 31, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PCT broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PCT entered a downward trend on August 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PCT's P/B Ratio (93.458) is very high in comparison to the industry average of (12.673). PCT has a moderately low P/E Ratio (0.000) as compared to the industry average of (85.420). PCT's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (2.034). PCT's Dividend Yield (0.000) is considerably lower than the industry average of (0.007). P/S Ratio (95.238) is also within normal values, averaging (281.124).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Industry description

Companies in the industrial specialties industry process basic materials and minerals into various specialty products, such as flat and safety glass, fire retardant products, paints and coatings. Examples of companies operating in this industry are Sherwin-Williams Company, PPG Industries, Inc. and RPM International Inc.

Market Cap

The average market capitalization across the Industrial Specialties Industry is 2.47B. The market cap for tickers in the group ranges from 344.07K to 23.97B. VLTO holds the highest valuation in this group at 23.97B. The lowest valued company is ATMFF at 344.07K.

High and low price notable news

The average weekly price growth across all stocks in the Industrial Specialties Industry was 0%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -12%. ADUR experienced the highest price growth at 17%, while RAIN experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Industrial Specialties Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was 35% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 78
P/E Growth Rating: 76
Price Growth Rating: 65
SMR Rating: 87
Profit Risk Rating: 91
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
PCT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry IndustrialSpecialties

Profile
Details
Industry
N/A
Address
20 North Orange Avenue
Phone
+1 877 648-3565
Employees
174
Web
https://www.purecycle.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.